Literature DB >> 10676662

Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.

J Jongsma1, M H Oomen, M A Noordzij, W M Van Weerden, G J Martens, T H van der Kwast, F H Schröder, G J van Steenbrugge.   

Abstract

Neuroendocrine (NE) cells are androgen-independent cells and secrete growth-modulating neuropeptides via a regulated secretory pathway (RSP). We studied NE differentiation after androgen withdrawal in the androgen-dependent prostate cancer xenograft PC-310. Expression patterns of chromogranin A, secretogranin III, and prohormone convertase-1 were analyzed at both protein and mRNA level to mark the kinetics of NE differentiation both in vivo and in vitro. PC-310 tumor-bearing nude mice were killed at 0, 2, 5, 7, 14, and 21 days postcastration. PC-310C cultures initiated from collagenase-treated tumor tissue could be maintained up to four passages, and androgen-deprivation experiments were performed similarly. PC-310 tumor volumes decreased by 50% in 10 days postcastration. Proliferative activity and prostate-specific antigen (PSA) serum levels decreased to zero postcastration, whereas PSA levels in PC-310C culture media first decreased and subsequently increased after 5 days. In vivo, androgen receptor (AR) expression decreased initially but returned to control level from 5 days postcastration on. CgA, secretogranin III, and secretogranin V expression increased in vivo from 5 days postcastration on. Subsequently, prohormone convertase-1 and peptidyl alpha-amidating monooxygenase as well as the vascular endothelial growth factor were expressed from 7 days postcastration on, and, finally, growth factors such as gastrin-releasing peptide and serotonin were expressed in a small part of the NE cells 21 days postcastration. The PC-310 tumors did not show colocalization of the AR on the NE cells in the tumor residues after 21 days. As in the PC-310 xenograft, NE differentiation was induced and AR expression relapsed after prolonged androgen suppression in PC-310C. For PC-310C cells, this relapse was associated with the secretion of PSA. PC-310C is the first culture of human prostatic cancer cells having the NE phenotype. The PC-310 model system is a potential androgen-dependent model for studying the role of NE cells in the progression of clinical prostate cancer. Androgen deprivation of NE-differentiated prostate cancer may induce the formation of both NE- and AR-positive dormant tumor residues, capable of actively producing NE growth factors via a RSP, possibly leading to hormone refractory disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10676662

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Lipid quantification by Raman microspectroscopy as a potential biomarker in prostate cancer.

Authors:  Jordan O'Malley; Rahul Kumar; Andrey N Kuzmin; Artem Pliss; Neelu Yadav; Srimmitha Balachandar; Jianmin Wang; Kristopher Attwood; Paras N Prasad; Dhyan Chandra
Journal:  Cancer Lett       Date:  2017-03-23       Impact factor: 8.679

2.  Generation of Prostate Cancer Patient-Derived Xenografts to Investigate Mechanisms of Novel Treatments and Treatment Resistance.

Authors:  Hung-Ming Lam; Holly M Nguyen; Eva Corey
Journal:  Methods Mol Biol       Date:  2018

3.  The Raf/MEK/extracellular signal-regulated kinase 1/2 pathway can mediate growth inhibitory and differentiation signaling via androgen receptor downregulation in prostate cancer cells.

Authors:  Seung-Keun Hong; Jin-Hwan Kim; Ming-Fong Lin; Jong-In Park
Journal:  Exp Cell Res       Date:  2011-08-16       Impact factor: 3.905

4.  Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer.

Authors:  S S Jeetle; G Fisher; Z H Yang; E Stankiewicz; H Møller; C S Cooper; J Cuzick; D M Berney
Journal:  Virchows Arch       Date:  2012-07-06       Impact factor: 4.064

5.  Neuroendocrine differentiation in prostate cancer.

Authors:  Yin Sun; Junyang Niu; Jiaoti Huang
Journal:  Am J Transl Res       Date:  2009-02-05       Impact factor: 4.060

6.  Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model.

Authors:  Wendy J Huss; Danny R Gray; Keyvan Tavakoli; Meghan E Marmillion; Lori E Durham; Mac A Johnson; Norman M Greenberg; Gary J Smith
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

7.  Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin A and androgen receptor positivity.

Authors:  M P Roudier; L D True; R L Vessella; C S Higano
Journal:  J Clin Pathol       Date:  2004-03       Impact factor: 3.411

8.  Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival.

Authors:  Audrey Dayon; Leyre Brizuela; Claire Martin; Catherine Mazerolles; Nelly Pirot; Nicolas Doumerc; Leonor Nogueira; Muriel Golzio; Justin Teissié; Guy Serre; Pascal Rischmann; Bernard Malavaud; Olivier Cuvillier
Journal:  PLoS One       Date:  2009-11-26       Impact factor: 3.240

9.  Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.

Authors:  W Nathaniel Brennen; Yezi Zhu; Ilsa M Coleman; Susan L Dalrymple; Lizamma Antony; Radhika A Patel; Brian Hanratty; Roshan Chikarmane; Alan K Meeker; S Lilly Zheng; Jody E Hooper; Jun Luo; Angelo M De Marzo; Eva Corey; Jianfeng Xu; Srinivasan Yegnasubramanian; Michael C Haffner; Peter S Nelson; William G Nelson; William B Isaacs; John T Isaacs
Journal:  JCI Insight       Date:  2021-04-22

10.  SCG3 Protein Expression in Glioma Associates With less Malignancy and Favorable Clinical Outcomes.

Authors:  Yi Wang; Nan Ji; Junmei Wang; Jingli Cao; Deling Li; Yang Zhang; Liwei Zhang
Journal:  Pathol Oncol Res       Date:  2021-02-26       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.